Compare VTGN & ARAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VTGN | ARAI |
|---|---|---|
| Founded | 1998 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.3M | 20.4M |
| IPO Year | 2014 | 2024 |
| Metric | VTGN | ARAI |
|---|---|---|
| Price | $0.27 | $0.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $0.90 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 2.8M | 542.7K |
| Earning Date | 06-16-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $113,250.00 |
| Revenue This Year | $124.49 | $800.66 |
| Revenue Next Year | $353.99 | $650.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.20 | $0.22 |
| 52 Week High | $5.14 | $6.86 |
| Indicator | VTGN | ARAI |
|---|---|---|
| Relative Strength Index (RSI) | 43.49 | 39.39 |
| Support Level | $0.21 | $0.22 |
| Resistance Level | $0.32 | $0.30 |
| Average True Range (ATR) | 0.02 | 0.03 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 44.89 | 52.62 |
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
Arrive AI Inc is a technology company. Its patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox-whether by drone, ground robot, or human courier. The platform provides real-time tracking, smart logistics alerts, and advance chain-of-custody controls to support shippers, delivery services, and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots, and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting, and security systems to streamline the entire last-mile delivery experience.